Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference

TEL AVIV, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine extended-release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Dr. Jonathan Rubin, Chief Medical Officer of Alcobra, will give a presentation entitled, "The Use of Biomarkers in Fragile X and Autism Clinical Trials," at Autism Speaks' Autism Investment Conference, being held at the Bently Reserve Banking Hall in San Francisco on March 4-5, 2014. The Alcobra presentation is on Tuesday, March 4, during the "Medicines and Therapeutic Devices" session.

Autism Investment Conference Presentation
Date: Tuesday, March 4, 2014
Time: 9am – 10am Pacific Time
Location: Company Showcase, "Medicines & Therapeutic Devices"

About the Autism Investment Conference

The Autism Investment Conference (AIC) is run by Autism Speaks, the international autism science and advocacy organization. The AIC is a forum for entrepreneurs, companies and investors to interact and explore opportunities, challenges and risks connected with new product development in autism today. In its second year, the AIC2014's goal is to help increase awareness and understanding of the diverse opportunity landscape in autism for new business development among the investment community. AIC2014 will introduce entrepreneurs and companies working on innovative products that address the unmet needs in patients with autism and related disorders.

About Alcobra Ltd.

Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MG01CI (Metadoxine Extended Release (MDX)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts: LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com

Source:Alcobra Ltd.